As N-cadherin antagonists (e.g., compound 15) block CAF adhesion and decrease their viability (Blaschuk 2020), they could be used to remodel fibrotic tumors, thus facilitating T cell-cancer cell interactions and drug delivery into tumors. The gene discussed is CDH2; the disease is cancer.